ABVC BioPharma, Inc. (NASDAQ: ABVC) has filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, highlighting a transformative year with substantial balance sheet growth. Total assets increased 179% to $21,062,203, up from $7,539,907 in 2024, driven primarily by strategic land acquisitions in Asia. Net property and equipment rose to $12,835,409 from $511,088, reflecting the acquisition of development-oriented land assets in Taiwan, with title transitions to ABVC and its subsidiary currently in process.
Management views this fiscal year as a structural strengthening of the company's balance sheet and asset foundation, supporting its unique licensing model. Under this model, ABVC has licensed its core drug programs to subsidiaries and related parties: the CNS pipeline to AiBtl BioPharma, oncology programs to OncoX BioPharma, and ophthalmology programs to ForSeeCon Eye Corporation. This structure allows subsidiaries to handle clinical development while ABVC reduces direct cash burn exposure and retains licensing economics and equity participation.
The company's strategic asset expansion in Taiwan includes two key properties. In Longtan District, Taoyuan, ABVC holds 5,995.41 square meters valued at $4.6 million as of December 31, 2025. This land is a strategic reserve with potential uses in healthcare, demonstration facilities, or supportive biotechnology infrastructure. In Puli Township, Nantou, a 69,230.90 square meter property was independently appraised at approximately $8.0 million as of January 30, 2026. The Puli development plan is a staged, long-term initiative focused on establishing a medicinal plant cultivation base, supporting pharmaceutical supply chain localization, and creating an agricultural-biotech integration platform. Projected annual cultivation and processing output value is estimated between $60,000 to $360,000, depending on processing depth.
Both land transfers are pending regulatory review and title registration under Taiwan's legal requirements. The Longtan property is registered under a related party landholder pending completion of review, while the Puli title transfer is under government review.
This evolution toward a hybrid asset model combines intellectual property, licensing revenue potential, equity participation in development subsidiaries, and tangible long-term physical assets. ABVC BioPharma is a clinical-stage biopharmaceutical company with six drugs and one medical device (ABV-1701/Vitargus®) under development. The company utilizes in-licensed technology from research institutions including Stanford University, University of California at San Francisco, and Cedars-Sinai Medical Center. For Vitargus®, the company intends to conduct pivotal Phase III trials through global partnerships.
Forward-looking statements in this release involve risks and uncertainties detailed in the company's SEC filings, available at http://www.sec.gov. The company assumes no obligation to update these statements.
